Browsing by Subject "Umbilical cord blood"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Hyperbaric oxygen improves engraftment of ex-vivo expanded and gene transduced human CD34+ cells in a murine model of umbilical cord blood transplantation
    (Elsevier B.V., 2014-01) Aljitawi, Omar S.; Xiao, Yinghua; Eskew, Jeff D.; Parelkar, Nikhil K.; Swink, Megan; Radel, Jeff; Lin, Tara L.; Kimler, Bruce F.; Mahnken, Jonathan D.; McGuirk, Joseph P.; Broxmeyer, Hal E.; Vielhauer, George; Department of Microbiology & Immunology, IU School of Medicine
    Delayed engraftment and graft failure represent major obstacles to successful umbilical cord blood (UCB) transplantation. Herein, we evaluated the use of hyperbaric oxygen (HBO) therapy as an intervention to improve human UCB stem/progenitor cell engraftment in an immune deficient mouse model. Six-to eight-week old NSG mice were sublethally irradiated 24 hours prior to CD34+ UCB cell transplant. Irradiated mice were separated into a non-HBO group (where mice remained under normoxic conditions) and the HBO group (where mice received two hours of HBO therapy; 100% oxygen at 2.5 atmospheres absolute). Four hours after completing HBO therapy, both groups intravenously received CD34+ UCB cells that were transduced with a lentivirus carrying luciferase gene and expanded for in vivo imaging. Mice were imaged and then sacrificed at one of 10 times up to 4.5 months post-transplant. HBO treated mice demonstrated significantly improved bone marrow, peripheral blood , and spleen (p=0.0293) retention and subsequent engraftment. In addition, HBO significantly improved peripheral, spleen and bone marrow engraftment of human myeloid and B-cell subsets. In vivo imaging demonstrated that HBO mice had significantly higher ventral and dorsal bioluminescence values. These studies suggest that HBO treatment of NSG mice prior to UCB CD34+ cell infusion significantly improves engraftment.
  • Thumbnail Image
    Item
    Insights into highly engraftable hematopoietic cells from 27-year cryopreserved umbilical cord blood
    (Elsevier, 2023) Broxmeyer, Hal E.; Luchsinger, Larry L.; Singer Weinberg, Rona; Jimenez, Alexandra; Masson Frenet, Emeline; Van't Hof, Wouter; Capitano, Maegan L.; Hillyer, Christopher D.; Kaplan, Mark H.; Cooper, Scott; Ropa, James; Microbiology and Immunology, School of Medicine
    Umbilical cord blood transplantation is a life-saving treatment for malignant and non-malignant hematologic disorders. It remains unclear how long cryopreserved units remain functional, and the length of cryopreservation is often used as a criterion to exclude older units. We demonstrate that long-term cryopreserved cord blood retains similar numbers of hematopoietic stem and progenitor cells compared with fresh and recently cryopreserved cord blood units. Long-term cryopreserved units contain highly functional cells, yielding robust engraftment in mouse transplantation models. We also leverage differences between units to examine gene programs associated with better engraftment. Transcriptomic analyses reveal that gene programs associated with lineage determination and oxidative stress are enriched in high engrafting cord blood, revealing potential molecular markers to be used as potency markers for cord blood unit selection regardless of length of cryopreservation. In summary, cord blood units cryopreserved for extended periods retain engrafting potential and can potentially be used for patient treatment.
  • Thumbnail Image
    Item
    Quickly attainable and highly engrafting hematopoietic stem cells
    (Wolters Kluwer, 2019-09-17) Broxmeyer, Hal E.; Microbiology and Immunology, School of Medicine